NOVAVAX INC (NVAX) - Dilution Analysis

10-Q filing | 163.3M shares outstanding

10-Q filing | 162.4M shares outstanding

8-K filing: Novavax, Inc. issued $225.0 million aggregate principal amount of its 4.625% Convertible Senior Notes due 2031, consisting of $175.3 million in exchange for $148.7 million of the Company's 5.00% Convertible Senior Notes due 2027 and $49.7 million for cash.

8-K filing: Novavax, Inc. entered into exchange and subscription agreements to issue $225.0 million aggregate principal amount of its 4.625% Convertible Senior Notes due 2031, consisting of $175.3 million in exchange for $148.7 million of 2027 Notes and $49.7 million for cash.

10-Q filing | 162.0M shares outstanding

10-Q filing | 161.0M shares outstanding

10-K filing | 152.2M shares outstanding

10-Q filing | 160.0M shares outstanding

10-Q filing | 165.9M shares outstanding

8-K filing: Novavax, Inc. sold and issued 6,880,481 shares of its common stock to Sanofi in a private placement at a price of $10.00 per share, resulting in gross proceeds of approximately $68.8 million. ($68.8M proceeds)

10-Q filing | 139.9M shares outstanding

10-K filing | 140.0M shares outstanding

10-Q filing | 118.8M shares outstanding

8-K filing: Novavax, Inc. filed a prospectus supplement for the sale of up to $500,000,000 of its common stock in at-the-market offerings. Since June 15, 2021, the Company sold 10.1 million shares of its common stock resulting in $247.4 million in net proceeds at a weighted average sales price of $24.69 per share pursuant to its At Market Issuance Sales Agreement with B. Riley Securities, Inc., dated as of June 15, 2021, leaving $249.5 million remaining under the June 2021 Sales Agreement. The Company and B. Riley Securities, Inc. terminated the June 2021 Sales Agreement by mutual agreement on the date hereof. ($247.4M proceeds)

10-Q filing | 89.4M shares outstanding

8-K filing: Novavax, Inc. entered into a Securities Subscription Agreement with SK bioscience Co., Ltd. to sell and issue 6,500,000 shares of common stock at a price of $13.00 per share, resulting in gross proceeds of approximately $84.5 million. ($84.5M proceeds)

10-Q filing | 86.2M shares outstanding

10-K filing | 78.2M shares outstanding

8-K filing: Novavax, Inc. completed an offering of $150 million aggregate principal amount of 5.00% Convertible Senior Notes due 2027 and may issue a maximum of 15,000,000 shares of common stock upon conversion of the Notes.

8-K filing: Novavax, Inc. announced a public offering of 6,500,000 shares of its common stock at $10.00 per share, and granted underwriters an option to purchase up to an additional 975,000 shares, which was fully exercised. Additionally, Novavax priced an offering of $150,000,000 aggregate principal amount of its 5.00% convertible senior notes due 2027. ($74.75M proceeds)

10-Q filing | 78.3M shares outstanding

10-Q filing | 78.1M shares outstanding

10-Q filing | 76.5M shares outstanding

10-K filing | 74.4M shares outstanding

10-Q filing | 74.7M shares outstanding

10-Q filing | 74.1M shares outstanding

8-K filing: Novavax, Inc. filed a prospectus supplement for the sale of up to $500,000,000 of shares of its common stock in at-the-market offerings. Since January 22, 2021, the Company sold 1.7 million shares of its common stock resulting in $451.9 million in net proceeds at a weighted average sales price of $271.65 per share pursuant to its At Market Issuance Sales Agreement with the Sales Agent, dated as of January 22, 2021, leaving $42.2 million remaining under the January 2021 Sales Agreement. The Company and the Sales Agent terminated the January 2021 Sales Agreement by mutual agreement on the date hereof. ($451.9M proceeds)

10-Q filing | 74.1M shares outstanding

10-K filing | 73.9M shares outstanding

8-K filing: Novavax, Inc. entered into an advanced purchase agreement with Canada for 52 million doses of NVX-CoV2373 and filed a prospectus supplement for the sale of up to $500,000,000 of shares of its common stock. Between November 10, 2020 and January 20, 2021, the Company sold 3.6 million shares of its common stock resulting in $466.8 million in net proceeds. ($466.8M proceeds)

8-K filing: Novavax, Inc. filed a prospectus supplement for the sale of up to $500,000,000 of shares of its common stock in at-the-market offerings. Between May 18, 2020 and November 5, 2020, the Company sold 3.4 million shares of its common stock resulting in $238.3 million in net proceeds at a weighted average sales price of $70.45 per share. ($238.3M proceeds)

10-Q filing | 63.7M shares outstanding

8-K filing: Novavax, Inc. filed a prospectus supplement to register for resale 4,421,766 shares of its common stock by selling stockholders, including shares issuable upon conversion of preferred stock and shares acquired in private placement financing transactions.

10-Q filing | 61.3M shares outstanding

8-K filing: Novavax, Inc. completed a private placement of Series A Convertible Preferred Stock and common stock on June 16, 2020, raising gross proceeds of approximately $201.5 million. ($201.5M proceeds)

8-K filing: Novavax, Inc. filed a prospectus supplement for the sale of up to $250,000,000 of common stock and sold 4.8 million shares of its common stock resulting in $99.3 million in net proceeds at a weighted average sales price of $21.08 per share pursuant to its At Market Issuance Sales Agreement with B. Riley FBR, Inc., dated as of March 2, 2020, fully utilizing the March 2020 Sales Agreement as of May 12, 2020. ($99.3M proceeds)

10-Q filing | 58.0M shares outstanding

10-K filing | 51.5M shares outstanding

8-K filing: Novavax, Inc. filed a prospectus supplement for the sale of up to $150,000,000 of shares of its common stock in at-the-market offerings. During the first quarter of 2020, the Company sold 10.5 million shares of its common stock resulting in $98.7 million in net proceeds at a weighted average sales price of $9.55 per share pursuant to its At Market Issuance Sales Agreement with B. Riley FBR, Inc., dated as of January 21, 2020. ($98.7M proceeds)